Biological products drawn from the start of life, like cord blood plasma and concentrated growth factors, carrying the proteins and signals the body uses to grow, repair, and regulate itself.
What Is It?
By Jed Ryan, Founder and CEO · Reviewed by Adas Darinskas, PhD, Chief Science Officer · Published · Last reviewed
Biologics are products made from living biological material rather than synthesized chemicals. The ones we coordinate come mostly from birth tissue, things like cord blood plasma, placental compounds, and concentrated growth factors. Because they come from the very start of life, they carry a dense mix of proteins, growth factors, and signaling molecules, the same substances the body uses to grow, repair, and regulate itself.
A lot of this is still early. The scientific interest is real and the mechanisms are plausible, but for most of these we don't yet have large human outcome trials proving benefit, and no one should read this as established therapy. We're honest about that. Biologics are used as part of a regenerative protocol, and the medical team decides where they fit your case.
The biologics we help people access are drawn from birth tissue and early-life biology, where the concentration of growth factors and signaling proteins is highest:
These are prepared and administered by the medical team at Innovita Clinic, often alongside stem cell or exosome protocols rather than on their own.
The main biological products in the regenerative toolkit.
The liquid fraction of umbilical-cord blood, dense with the growth factors and signaling proteins the body uses from the start of life.
A developmental protein found in cord blood that acts as an immunomodulator, studied for its role in regulating immune activity.
A concentrated preparation of the growth factors that drive tissue repair and recovery.
A compound prepared from placental tissue and used to support regeneration.
Biological products drawn from birth tissue, where the regenerative signaling is richest.
Most often delivered alongside stem cell or exosome therapy, where the medical team decides they add value, rather than on their own.
Active areas of research, from tissue repair to immune regulation and longevity. These are not proven cures; they're where the science and our protocols point.
Growth factors are the body's own repair signals, so most of the interest in biologics sits here: helping tissue heal and recover. Areas under study include:
Some of these compounds, alpha-fetoprotein in particular, appear to act as immunomodulators, meaning they help regulate immune activity rather than broadly switch it on or off. This is an early but active area of research for:
Part of the interest in birth-tissue biologics is simple: they carry the signaling of early-life biology. That makes them a focus of longevity and recovery research, used as part of broader optimization protocols:
Biologics like cord blood plasma and growth factors are an active area of study, with preclinical and early clinical research underway. The results so far are promising but not yet proven, so explore the research and judge for yourself.
Explore the ResearchFour steps from our first conversation to your treatment. We carry the complicated parts so you don't have to.
An exploratory conversation with Jed, for us to understand what you've been dealing with and how we can best help.
A Zoom consultation with Dr. Adas Darinskas and the medical team to look at your case honestly and talk through whether a regenerative protocol makes sense for you.
We build your protocol with Dr. Darinskas and his team, combining the therapies that fit your case and the goal you're after.
You receive treatment at Innovita Clinic in Vilnius, or at one of our partner facilities, wherever fits your case best. We work alongside you on scheduling and point you in the right direction for travel and accommodation.
Client stories and testimonials, coming soon.
We're gathering stories from clients who've been through biologic therapies. Check back soon, or reach out to talk with the team about client experiences.
Start the Conversation